WO2021074778A1 - An industrial process for resolution of chlocyphos - Google Patents
An industrial process for resolution of chlocyphos Download PDFInfo
- Publication number
- WO2021074778A1 WO2021074778A1 PCT/IB2020/059589 IB2020059589W WO2021074778A1 WO 2021074778 A1 WO2021074778 A1 WO 2021074778A1 IB 2020059589 W IB2020059589 W IB 2020059589W WO 2021074778 A1 WO2021074778 A1 WO 2021074778A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- chlocyphos
- isomer
- solvent
- acid
- Prior art date
Links
- ZPSPULCZMWMHCY-JTQLQIEISA-N (4r)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2$l^{5}-dioxaphosphinane 2-oxide Chemical compound CC1(C)COP(O)(=O)O[C@H]1C1=CC=CC=C1Cl ZPSPULCZMWMHCY-JTQLQIEISA-N 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 26
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 claims abstract description 7
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 5
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 229940011051 isopropyl acetate Drugs 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- AFINAILKDBCXMX-PBHICJAKSA-N (2s,3r)-2-amino-3-hydroxy-n-(4-octylphenyl)butanamide Chemical compound CCCCCCCCC1=CC=C(NC(=O)[C@@H](N)[C@@H](C)O)C=C1 AFINAILKDBCXMX-PBHICJAKSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 0 CCC(CC)C(C(C)(C)Cc1ccccc1Cl)OP(*)(O)=O Chemical compound CCC(CC)C(C(C)(C)Cc1ccccc1Cl)OP(*)(O)=O 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- -1 cyclic phosphoric acid derivatives Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JUCGVCVPNPBJIG-UHFFFAOYSA-N 2-amino-1-phenylpropane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=CC=C1 JUCGVCVPNPBJIG-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- LJCWONGJFPCTTL-UHFFFAOYSA-N 4-hydroxyphenylglycine Chemical compound OC(=O)C(N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-UHFFFAOYSA-N 0.000 description 1
- ZPSPULCZMWMHCY-SNVBAGLBSA-N CC(C)(CO1)[C@@H](c2ccccc2Cl)OP1(O)=O Chemical compound CC(C)(CO1)[C@@H](c2ccccc2Cl)OP1(O)=O ZPSPULCZMWMHCY-SNVBAGLBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 description 1
- 229960000508 bedaquiline Drugs 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to a process for resolution of Chlocyphos of formula (I) to obtain corresponding (S)-or (R)-isomer.
- the present invention further relates to a process of obtaining (S) -Chlocyphos using (R)-(+)-a- methylbenzylamine and (R) -Chlocyphos using (S)-(-)-a-methylbenzylamine.
- the said resolution process provides the corresponding isomer with chiral purity more than 98%.
- Chlocyphos of formula (I) having CAS No. 98634-28-7 is acyclic phosphoric acid derivative
- an optically active isomer of chlocyphos is an effective resolving agent to separate optically active isomers of various intermediates and pharmaceutical agents.
- the optically active isomers of chlocyphos is used in resolving various compounds such as Bedaquiline, D-serine, Metoprolol, Rotigotine, Valine etc.
- Various resolving agents are disclosed for the resolution of racemic chlocyphos to its active (R)-or(S)-isomer.
- the US 6,800,778Bl discloses various cyclic phosphoric acid derivatives and they were separated by optical resolution using different chiral amines. It further discloses the difficulty of finding which (optically) active amino compound is suitable for the resolution of a particular cyclic phosphoric acid derivative because optical amines vary based on specific cyclic phosphoric acid derivative. Though there are plenty of resolving agents available in the art, only few may practically useful. Therefore, it is necessary to screen several resolving agents to find a good combination of racemate and resolving agent.
- the present invention provides a resolution of chlocyphos using optically active a-methylbenzylamine to obtain corresponding isomers. It enables resolution of chlocyphos using a cost effective resolving agent by diastereomeric salt formation.
- the present invention also includes the recovery and further racemization of undesired isomer.
- the main object of the present invention is to provide a resolution process of a Chlocyphos of formula (I) using suitable resolving agent.
- the other object of the present invention is to provide a resolution process of a chlocyphos of formula (I) using suitable resolving agent to obtain corresponding isomers with chiral purity greater than 98%.
- Another objective of the present invention is to provide a process for the resolution of a chlocyphos of formula (I), which is simple and commercially viable.
- the present invention provides a process for resolution of Chlocyphos of formula (I) to obtain an optically active isomers, which comprises the steps: a) treating a Chlocyphos of formula (I) with an optically active a- methylbenzylamine as resolving agent in a solvent to obtain corresponding diastereo meric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain an optically active desired enantiomer; c) optionally recovering the undesired isomer.
- the present invention provides a process for resolution of Chlocyphos of formula (I) to get (S)-isomer, which comprises the steps: a) treating a Chlocyphos of formula (I) with (R)-(+)-a-methylbenzylamine in a solvent to obtain diastereomeric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain a (S)- Chlocyphos of formula (lb);
- the present invention provides a process for resolution of Chlocyphos of formula (I) to obtain corresponding (R)-isomer, which comprises the steps: a) treating a Chlocyphos of formula (I) with (S)-(-)-a-methylbenzylamine in a solvent to obtain diastereo meric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain a (R)- Chlocyphos of formula (la); c) optionally recovering the undesired (S)-isomer of formula (lb).
- the present invention provides a process for recovery of undesired isomer of Chlocyphos comprises the steps: a) treating any one of diastereomeric salt with an acid; b) filtering the reaction mixture to obtain solid; c) washing with water and drying the solid to obtain corresponding (R)-isomer or (S)-isomer.
- the instant invention relates to a process for resolution of Chlocyphos of formula (I) to obtain corresponding (S)- or (R)- isomers.
- the (R)-chlocyphos of formula (la) and (S)-chlocyphos of formula (lb) are respectively known as(R)-(+)-4-(2- chlorophenyl)-5,5-dimethyl-2-hydroxy-l,3,2-dioxaphosphinane 2-oxide and (S)-(- )-4-(2-chlorophenyl)-5,5-dimethyl-2-hydroxy-l,3,2-dioxaphosphinane 2-oxide.
- the present invention enables resolution of chlocyphos of formula (I) by diastereomeric salt formation with (R)-(+)-a-methylbenzylamine or (S)-(-)-a- methylbenzylamine as resolving agent to obtain salt of corresponding (S)- or (R)- isomers respectively; further treating the diastereomeric salt of corresponding (S)- or (R)-isomers with an acid to get pure enantiomer (S)-chlocyphos or (R)- chlocyphos and optionally recovering undesired enantiomer separately.
- the said resolution process provides the corresponding isomer with chiral purity more than
- solvent used herein refers to the single solvent or mixture of solvents.
- a solvent used in step (a) is selected from a group consisting of water, alcoholic solvents such as methanol, ethanol, isopropanol; acetate solvents such as ethyl acetate, isopropyl acetate and the like.
- step (b) wherein the said acid used in step (b) is selected from a group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and the like.
- a solvent used in step (b) is selected from a group consisting of water, alcoholic solvents such as methanol, ethanol, isopropanol; acetate solvents such as ethyl acetate, isopropyl acetate and the like.
- the instant invention produces (S)-Chlocyphos (lb) using (R)-(+)-a- methylbenzylamine which is readily available at low price.
- step (a) is 1-10 hours; step (b) is 2-6 hours; and step (c) is 1-3 hours.
- optically active enantiomer of formula (la) or (lb) is obtained with chemical purity greater than 98% and chiral purity greater than 98%.
- racemic chlocyphos of formula (I) is prepared by process illustrated in synthetic scheme 2.
- the ethanol (42 mL, 6V) and racemic chlocyphos (7 g, 0.0253 mol, 1 eq) were charged in reactor and stirred for 15-30 min at rt.
- the S-(-)-a-methyl benzyl amine (3.0 g, 0.0254 mol, 1 eq) was added and stirred for 15-30 min at rt.
- the reaction mass was heated to reflux and maintained for 2 h.
- the reaction mass was cooled to 20°C to 30°C and stirred for 8 h.
- the slurry was filtered and washed with ethanol.
- the wet cake and ethanol (21 mL) were taken in reactor and heated to reflux for 2 h.
- the ethanol (420 L, 6V) and racemic chlocyphos (70 Kg, 253 mol, 1 eq) were charged in a reactor and stirred for 15-30 min at rt.
- the R-(+)-a-methyl benzyl amine (30.8 Kg, 254.2 mol, 1 eq) was added and stirred for 15-30 min at rt.
- the reaction mass was heated to reflux and maintained for 1 to 5 h.
- the reaction mass was cooled and stirred for 8 h.
- the slurry was filtered and washed with ethanol.
- the wet cake and ethanol (210 L) were taken in reactor and heated to reflux for 2 h.
- the reaction mass was cooled and stirred for 2 h.
- the filtrate (obtained from example 1 or 2) was distilled-out up to minimum volume. To this, 20% HC1 was added and the reaction mixture was stirred for 3h at 20°C to 40°C to get the solid. The solid was filtered, washed with water and dried to obtain the corresponding isomer.
- the filtrate (obtained from example 1 or 2) was distilled out up to minimum volume. To this, 20% HC1 was added (5 V) and the reaction mixture was stirred for 3h at 20°C to 40°C to get the solid. The solid was filtered, washed with water and dried at 55°C to 65°C to obtain(R)-Chlocyphos as a white solid (yield: 32%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)- isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-(-)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
Description
AN INDUSTRIAL PROCESS FOR RESOLUTION OF CHLOCYPHOS
RELATED APPLICATION
This application claims the benefit to Indian Provisional Application No. IN201921041836, filed on Oct 16, 2019, the contents of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to a process for resolution of Chlocyphos of formula (I) to obtain corresponding (S)-or (R)-isomer. The present invention further relates to a process of obtaining (S) -Chlocyphos using (R)-(+)-a- methylbenzylamine and (R) -Chlocyphos using (S)-(-)-a-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
BACKGROUND OF THE INVENTION
Chlocyphos of formula (I) having CAS No. 98634-28-7 is acyclic phosphoric acid derivative, an optically active isomer of chlocyphos is an effective resolving agent to separate optically active isomers of various intermediates and pharmaceutical agents. The optically active isomers of chlocyphos is used in resolving various compounds such as Bedaquiline, D-serine, Metoprolol, Rotigotine, Valine etc.
Various resolving agents are disclosed for the resolution of racemic chlocyphos to its active (R)-or(S)-isomer. One of the resolving agent (-)-(p- hydroxyphenylglycine) was known to separate chlocyphos to get corresponding (S)-Chlocyphos ( JOC , 1985, 50(23), 4508-14), however it is not economically viable reagent in industrial scale.
The US 6,800,778Bldiscloses various cyclic phosphoric acid derivatives and they were separated by optical resolution using different chiral amines. It further discloses the difficulty of finding which (optically) active amino compound is suitable for the resolution of a particular cyclic phosphoric acid derivative because optical amines vary based on specific cyclic phosphoric acid derivative. Though there are plenty of resolving agents available in the art, only few may practically useful. Therefore, it is necessary to screen several resolving agents to find a good combination of racemate and resolving agent. Most of the phosphoric acids including chlocyphos were separated using (-)-ephedrine,(-)-(p-hydroxyphenyl) glycine, (+)-2-amino- 1-phenyl- 1,3-propanediol, however, these reagents are not commercially viable.
First time, the present invention provides a resolution of chlocyphos using optically active a-methylbenzylamine to obtain corresponding isomers. It enables resolution of chlocyphos using a cost effective resolving agent by diastereomeric salt formation. The present invention also includes the recovery and further racemization of undesired isomer.
SUMMARY OF THE INVENTION
The main object of the present invention is to provide a resolution process of a Chlocyphos of formula (I) using suitable resolving agent.
The other object of the present invention is to provide a resolution process of a chlocyphos of formula (I) using suitable resolving agent to obtain corresponding isomers with chiral purity greater than 98%.
Another objective of the present invention is to provide a process for the resolution of a chlocyphos of formula (I), which is simple and commercially viable.
In one aspect, the present invention provides a process for resolution of Chlocyphos of formula (I) to obtain an optically active isomers, which comprises the steps:
a) treating a Chlocyphos of formula (I) with an optically active a- methylbenzylamine as resolving agent in a solvent to obtain corresponding diastereo meric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain an optically active desired enantiomer; c) optionally recovering the undesired isomer.
In another aspect, the present invention provides a process for resolution of Chlocyphos of formula (I) to get (S)-isomer, which comprises the steps: a) treating a Chlocyphos of formula (I) with (R)-(+)-a-methylbenzylamine in a solvent to obtain diastereomeric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain a (S)- Chlocyphos of formula (lb);
(la) (lb) c) optionally recovering the undesired (R)-isomer of Formula (la).
In another aspect, the present invention provides a process for resolution of Chlocyphos of formula (I) to obtain corresponding (R)-isomer, which comprises the steps: a) treating a Chlocyphos of formula (I) with (S)-(-)-a-methylbenzylamine in a solvent to obtain diastereo meric salt; b) treating the diastereomeric salt with an acid in a solvent to obtain a (R)- Chlocyphos of formula (la);
c) optionally recovering the undesired (S)-isomer of formula (lb).
In yet another aspect, the present invention provides a process for recovery of undesired isomer of Chlocyphos comprises the steps: a) treating any one of diastereomeric salt with an acid; b) filtering the reaction mixture to obtain solid; c) washing with water and drying the solid to obtain corresponding (R)-isomer or (S)-isomer.
DETAILED DESCRIPTION OF THE INVENTION
The present invention now is described in more detail hereinafter. The invention is embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. As used in the specification, and in the appended claims, the singular forms “a”, “an”, “the”, include plural referents unless the context clearly indicates otherwise.
The instant invention relates to a process for resolution of Chlocyphos of formula (I) to obtain corresponding (S)- or (R)- isomers. The (R)-chlocyphos of formula (la) and (S)-chlocyphos of formula (lb) are respectively known as(R)-(+)-4-(2-
chlorophenyl)-5,5-dimethyl-2-hydroxy-l,3,2-dioxaphosphinane 2-oxide and (S)-(- )-4-(2-chlorophenyl)-5,5-dimethyl-2-hydroxy-l,3,2-dioxaphosphinane 2-oxide.
The present invention enables resolution of chlocyphos of formula (I) by diastereomeric salt formation with (R)-(+)-a-methylbenzylamine or (S)-(-)-a- methylbenzylamine as resolving agent to obtain salt of corresponding (S)- or (R)- isomers respectively; further treating the diastereomeric salt of corresponding (S)- or (R)-isomers with an acid to get pure enantiomer (S)-chlocyphos or (R)- chlocyphos and optionally recovering undesired enantiomer separately. The said resolution process provides the corresponding isomer with chiral purity more than
98%.
The above process is illustrated in the following general synthetic scheme 1: Scheme 1:
The term solvent used herein, refers to the single solvent or mixture of solvents.
In another embodiment of the present invention, wherein a solvent used in step (a) is selected from a group consisting of water, alcoholic solvents such as methanol, ethanol, isopropanol; acetate solvents such as ethyl acetate, isopropyl acetate and the like.
In another embodiment of the present invention, wherein the said acid used in step (b) is selected from a group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and the like.
In another embodiment of the present invention, wherein a solvent used in step (b) is selected from a group consisting of water, alcoholic solvents such as methanol, ethanol, isopropanol; acetate solvents such as ethyl acetate, isopropyl acetate and the like.
The instant invention produces (S)-Chlocyphos (lb) using (R)-(+)-a- methylbenzylamine which is readily available at low price.
In another embodiment of the present invention, the reaction temperature of: step (a) is 20°C to 85° C; step (b) is 20°C to 85°C; and step (c) is 20°C to 40°C.
In another embodiment of the present invention, wherein the reaction time of: step (a) is 1-10 hours; step (b) is 2-6 hours; and step (c) is 1-3 hours.
In another embodiment of the present invention, wherein the optically active enantiomer of formula (la) or (lb) is obtained with chemical purity greater than 98% and chiral purity greater than 98%.
In another embodiment of the present invention, wherein the racemic chlocyphos of formula (I) is prepared by process illustrated in synthetic scheme 2.
Scheme 2:
In another embodiment of the present invention, wherein the process illustrated in synthetic scheme 2 for preparation of racemic chlocyphos of formula (I) comprises: (i) reacting 2-chloro benzaldehyde of formula (II) and
isobutyraldehyde of formula (III) in presence of base in a solvent to obtain compound of formula (IV);
(ii) treating compound of formula (IV) with chlorinating agent in a solvent to obtain compound of formula (V);
(iii) treating compound of formula (V) with a base in solvent to obtain racemic chlocyphos of formula (I).
In another embodiment of the present invention, wherein all the crude compound is used as such or purified by distillation or crystallization or by different techniques well understood by those skilled in the art.
The preparation of the starting materials and reagents used in the present invention are well known in prior art.
The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.
Experimental
Example 1: Resolution of Chlocyphos using (S)-(-)-a-methylbenzylamine to obtain (R)-chlocyphos (la)
The ethanol (42 mL, 6V) and racemic chlocyphos (7 g, 0.0253 mol, 1 eq) were charged in reactor and stirred for 15-30 min at rt. The S-(-)-a-methyl benzyl amine (3.0 g, 0.0254 mol, 1 eq) was added and stirred for 15-30 min at rt. The reaction mass was heated to reflux and maintained for 2 h. The reaction mass was cooled to 20°C to 30°C and stirred for 8 h. The slurry was filtered and washed with ethanol. The wet cake and ethanol (21 mL) were taken in reactor and heated to reflux for 2 h. The reaction mass was cooled to 20°C to 30°C and stirred for 2 h. The slurry was filtered and washed with ethanol. The filtrate was separately treated to recover undesired enantiomer. The wet cake and diluted hydrochloric acid (HC1) (21 mL) were stirred at rt for 3-6 h. The slurry was filtered and washed with water and dried to yield the product as white solid (yield: 2.38 g (34% yield), [a]578 + 49°; purity by HPLC 99.62% and chiral purity 97.30%.
Ή-NMR (CDCI3, 400MHz): 7.38-7.50 (m, 4H), 5.66 (d, 1H, J = 1.6 Hz), 4.21 (d, 1H, J = 11.2Hz), 3.87-3.96 (m, 1H), 1.00 (s, 3H), 0.73 (s, 3H);
Example 2: Resolution of Chlocyphos using (R)-(+)-a-methylbenzylamineto obtain (S)-chlocyphos (lb)
The ethanol (420 L, 6V) and racemic chlocyphos (70 Kg, 253 mol, 1 eq) were charged in a reactor and stirred for 15-30 min at rt. The R-(+)-a-methyl benzyl amine (30.8 Kg, 254.2 mol, 1 eq) was added and stirred for 15-30 min at rt. The reaction mass was heated to reflux and maintained for 1 to 5 h. The reaction mass was cooled and stirred for 8 h. The slurry was filtered and washed with ethanol. The wet cake and ethanol (210 L) were taken in reactor and heated to reflux for 2 h. The reaction mass was cooled and stirred for 2 h. The slurry was filtered and washed with ethanol. The filtrate was separately treated to recover another enantiomer. The wet cake and dilute hydrochloric acid (HC1) (210 L) were stirred at rt for 3-6 h. The slurry was filtered and washed with water and dried to yield the product as white solid (yield: 23.8 Kg (34% yield), [a]578 -49°; purity by HPLC 99.97% and chiral purity 98.66%.
Ή-NMR (CDCI3, 400MHz): 7.38-7.50 (m,4H), 5.66 (d, 1H, J = 2Hz), 4.21 (d, 1H, J = 11.2Hz), 3.87-3.96 (m, 1H), 1.00 (s, 3H), 0.73 (s, 3H);
13C-NMR (DMSO-d6, 400MHz): 134.08, 133.98, 131.98, 130.15, 130.07, 129.33, 127.04, 81.23, 81.18, 77.20, 77.14, 36.84, 36.81, 20.01, 17.35.
General process for recovery of (S)-Chlocyphos or (R)- Chlocyphos
The filtrate (obtained from example 1 or 2) was distilled-out up to minimum volume. To this, 20% HC1 was added and the reaction mixture was stirred for 3h at 20°C to 40°C to get the solid. The solid was filtered, washed with water and dried to obtain the corresponding isomer.
Example 3: Process for recovery of (R)-Chlocyphos (la)
The filtrate (obtained from example 1 or 2) was distilled out up to minimum volume. To this, 20% HC1 was added (5 V) and the reaction mixture was stirred
for 3h at 20°C to 40°C to get the solid. The solid was filtered, washed with water and dried at 55°C to 65°C to obtain(R)-Chlocyphos as a white solid (yield: 32%).
Claims
1. A resolution process of Chlocyphos of formula (I) to obtain active isomers, which comprises the steps of:
a) treating a Chlocyphos of formula (I) with an optically active a- methylbenzylamine resolving agent in a solvent to obtain diastereo meric salt;
Diastereomeric salts b) treating the diastereomeric salt with an acid in a solvent to obtain an optically active desired enantiomer of formula (la) or (lb);
Diastereomeric salts c) optionally recovering the undesired isomer.
2. The process as claimed in claim 1, wherein the optically active a-methylbenzylamine used in step (a) is selected from S-(-)-a- methyl benzyl amine and R-(+)-a- methyl benzyl amine.
3. The process as claimed in claim 1, wherein an active isomer of formula (lb), comprises the steps of:
a) treating a Chlocyphos of formula (I) with (R)-(+)-a-methylbenzylamine in a solvent to obtain diastereo meric salt; b) treating the diastereo meric salt with an acid in a solvent to obtain a (S)- Chlocyphos of formula (lb); c) optionally recovering undesired (R)-isomer of Formula (la).
4. The process as claimed in claim 1 wherein an active isomer of formula (la), which comprises the steps of: a) treating a Chlocyphos of formula (I) with (S)-(-)-a-methylbenzylamine in a solvent to obtain diastereo meric salt; b) treating the diastereo meric salt with acid in a solvent to obtain a (R)- Chlocyphos of formula (la); c) optionally recovering undesired (S)-isomer of formula (lb).
5. The process as claimed in claim 1, 3 or 4, wherein the solvent used in step (a) and step (b) is selected from a group consisting of water, alcoholic solvents such as methanol, ethanol, isopropanol; acetate solvent such as ethyl acetate and isopropyl acetate.
6. The process as claimed in claim 1, 3 or 4, wherein a recovery of undesired isomer, which comprises the steps of: a) treating diastereomeric salt with an acid; b) filtering the reaction mixture to obtain solid; c) washing with water and drying the solid to obtain (R)-isomer (la) or (S)- isomer (lb).
7. The process as claimed in claim 1, 3, 4 or 6, wherein the acid used is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20876999.2A EP4045615A4 (en) | 2019-10-16 | 2020-10-13 | An industrial process for resolution of chlocyphos |
| JP2022523199A JP2022553028A (en) | 2019-10-16 | 2020-10-13 | Industrial method of splitting crocyphos |
| US17/769,718 US20220389040A1 (en) | 2019-10-16 | 2020-10-13 | An industrial process for resolution of chlocyphos |
| CA3154610A CA3154610A1 (en) | 2019-10-16 | 2020-10-13 | An industrial process for resolution of chlocyphos |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921041836 | 2019-10-16 | ||
| IN201921041836 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021074778A1 true WO2021074778A1 (en) | 2021-04-22 |
Family
ID=75538630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2020/059589 WO2021074778A1 (en) | 2019-10-16 | 2020-10-13 | An industrial process for resolution of chlocyphos |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220389040A1 (en) |
| EP (1) | EP4045615A4 (en) |
| JP (1) | JP2022553028A (en) |
| CA (1) | CA3154610A1 (en) |
| WO (1) | WO2021074778A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235927B1 (en) * | 1996-10-23 | 2001-05-22 | Dsm N.V. | Process for the separation of a mixture of enantiomers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101717392A (en) * | 2009-10-09 | 2010-06-02 | 苏州凯达生物医药技术有限公司 | Method for preparing rotigotine and derivative thereof |
-
2020
- 2020-10-13 US US17/769,718 patent/US20220389040A1/en active Pending
- 2020-10-13 JP JP2022523199A patent/JP2022553028A/en active Pending
- 2020-10-13 EP EP20876999.2A patent/EP4045615A4/en not_active Withdrawn
- 2020-10-13 WO PCT/IB2020/059589 patent/WO2021074778A1/en unknown
- 2020-10-13 CA CA3154610A patent/CA3154610A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235927B1 (en) * | 1996-10-23 | 2001-05-22 | Dsm N.V. | Process for the separation of a mixture of enantiomers |
Non-Patent Citations (2)
| Title |
|---|
| DR. F. ZWARTS: "Resolutions of Racemates by Crystallization Additives and Attrition, Rector Magnificus", UNIVERSITY OF GRONINGEN, 20 September 2009 (2009-09-20), pages 1 - 203, XP055816449, Retrieved from the Internet <URL:https://core.ac.uk/download/pdf/12939778.pdf> * |
| See also references of EP4045615A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4045615A1 (en) | 2022-08-24 |
| JP2022553028A (en) | 2022-12-21 |
| CA3154610A1 (en) | 2021-04-22 |
| US20220389040A1 (en) | 2022-12-08 |
| EP4045615A4 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5202519B2 (en) | (R)-(−)-3- (Carbamoylmethyl) -5-methylhexanoic acid, pregabalin, and synthetic intermediate production method | |
| KR101699095B1 (en) | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | |
| CZ374297A3 (en) | Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid | |
| WO2008062460A2 (en) | Crystalline forms of pregabalin | |
| US20180134660A1 (en) | Process for the enantiomeric resolution of apremilast intermediates | |
| WO2017118928A9 (en) | Process for the separation of diastereomers of tenofovir alafenamide | |
| EP2681186B1 (en) | Process of resolution of 1-aminoindan | |
| JP4906511B2 (en) | Method for resolution of optionally substituted mandelic acid by salt formation with a chiral base cyclic amide | |
| TW201837047A (en) | Process for the preparation of d-glufosinate or salts thereof using ephedrine | |
| WO2006008171A1 (en) | Process for the preparation of a diastereomerically enriched compound | |
| US20080015385A1 (en) | Preparation of (S)-pregabalin-nitrile | |
| WO2021074778A1 (en) | An industrial process for resolution of chlocyphos | |
| JPH06184091A (en) | Process for preparation of optically active methioninamide | |
| US7829702B2 (en) | Racemic separation of 2,6-trans-dimethymorpholine | |
| US20050085545A1 (en) | Cycloalkylaminoacid compounds, processes for making and uses thereof | |
| JPH09157229A (en) | Racemization of optically active 1-phenylethylamine derivative | |
| US7385080B2 (en) | Method for producing optically active β-phenylalanine compounds | |
| JP3005669B2 (en) | Method for producing asymmetric fluorinated primary amines | |
| US8212072B2 (en) | Process for the preparation of pregabalin | |
| EP0411074A1 (en) | Resolution process | |
| JP3552260B2 (en) | Optical resolution of 1-amino-2-indanols | |
| JP3694923B2 (en) | Process for producing optically active 1- (2,4-dichlorophenyl) ethylamine | |
| KR20040035568A (en) | Process for Racemate Resolution of 3-Aminopentanenitrile | |
| JP3738470B2 (en) | Process for producing optically active 1- (dichloro-substituted phenyl) ethylamines | |
| JP2000512643A (en) | Process for producing optically active 1-phenylethylamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20876999 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3154610 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2022523199 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020876999 Country of ref document: EP Effective date: 20220516 |